Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors

You may be eligible if

• Criteria:
• Histologically confirmed solid tumors
• Measurable or nonmeasurable disease: No serum tumor marker elevation as the only evidence of disease; Patients with ovarian or endometrial cancer must have measurable disease, defined as \>= 1 lesion \>= 20 mm by conventional techniques OR \>= 10 mm by spiral CT scan
• Advanced disease; Refractory to standard therapy OR no standard therapy is available
• Carboplatin and paclitaxel considered reasonable therapeutic option
• No known brain metastases
• ECOG performance status 0-1
• Life expectancy \>= 12 weeks
• Absolute granulocyte count \>= 1,500/mm\^3
• Platelet count \>= 100,000/mm\^3
• Bilirubin =\< 1.5 times upper limit of normal (ULN)
• AST and ALT =\< 3 times ULN (5 times ULN if documented liver metastases)
• Fasting serum cholesterol =\< 9.0 mmol/L
• Fasting triglycerides =\< 4.56 mmol/L
• Creatinine normal OR creatinine clearance \>= 50 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Accessible for treatment and follow up
• No serious cardiovascular illness, including any of the following:
• myocardial infarction within the past 6 months, congestive heart failure (even if medically controlled), unstable angina, active cardiomyopathy, cardiac arrhythmia, uncontrolled hypertension
• No preexisting sensory or motor neuropathy \>= grade 2 due to previous chemotherapy; Local or regional neurological findings related to previous injury or disease allowed
• No hearing loss \>= grade 2 from any cause
• No history of allergic reactions attributed to compounds of similar chemical or biological composition to temsirolimus
• No serious illness or medical condition that would preclude study treatment including, but not limited to, any of the following: History of significant neurologic or psychiatric disorder that would impair the ability to obtain consent or limit study compliance, Active uncontrolled infection or nonhealing wounds, OR;
• At least 4 weeks since prior radiotherapy (except low-dose, palliative radiotherapy) and recovered
• At least 4 weeks since prior chemotherapy and recovered
• No more than 2 prior chemotherapy regimens
• Prior therapy with carboplatin and/or paclitaxel allowed provided the patient has no persistent related toxicity \>= grade 1 AND retreatment with the combination is clinically indicated (e.g., second-line therapy for ovarian cancer with \> 6-month treatment-free interval)
• At least 21 days since prior major surgery and recovered
• No prior mTOR inhibitor
• No concurrent prophylactic hematopoietic colony-stimulating factors
• No other concurrent anticancer therapy or investigational agents
• Active peptic ulcer disease, Any other medical condition that might be aggravated by treatment